



AM Biotechnologies, LLC



Contact:
Mark Shumbera

Location:
Houston, Texas

Email:
mark.shumbera@am-biotech.com

Tel:
832.295.1483

Website:
<http://www.am-biotech.com>



Company Profile

Industry Sector: Life Science Research; Affinity Agents

Company Overview: AM Biotech is a development-stage biotechnology company based in Houston, Texas that developed X-Aptamers, a synthetic affinity molecule platform. The company's mission is to be the largest, most comprehensive source for high quality synthetic affinity agents for use in a wide array of products in every life science market.

Target Market(s): Research, Academic, Small Biotech



Key Value Drivers

Technology*: X-Aptamer synthetic affinity molecule platform; short strands of DNA with amino acid functional groups

Competitive Advantage: The X-Aptamer discovery process is rapid. It's easy to use and kit packaging enables customers to discover X-Aptamer affinity agents to several targets simultaneously using only standard laboratory equipment. Reduces the market price for aptamer discovery by >10X.

Plan & Strategy: X-Aptamer Selection Kit is priced very aggressively with sample generated using the kit processed at no charge in exchange for AM Biotech sharing the commercial rights of the resulting X-Aptamers with the customer. Quickly build an extensive e-commerce catalog of crowd-sourced, user validated X-Aptamers.



Management

Leadership:

Mark Shumbera, MBA: President, Board
David Gorenstein, PhD: Chief Science Officer, Board
Xianbin Yang, PhD, MBA: Director, R&D

Scientific Advisory Board:

Bruce Luxon, PhD: Director UTMB Bioinformatics Center (retired)



Product Pipeline



- Pipeline One:** The X-Aptamer Selection Kit offered under the No Risk X-Aptamer Development model that results in an e-commerce catalog of crowd-sourced, user validated X-Aptamers to thousands of targets
- Pipeline Two:** Turn-key X-Aptamer selection service
- Pipeline Three:** Unique, chemically-modified DNA and RNA phosphoramidites